Startup launches with $245 million for twice yearly asthma treatment

A new biotech has raised $245 million to test a new asthma medication that could compete with one sold by Amgen and AstraZeneca.

The startup, Aiolos Therapeutics, was founded by former Genentech colleagues Khurem Farooq and Tony Adamis after they stumbled upon a drug being developed by Chinese pharma company Jiangsu Hengrui Pharmaceuticals Co., Ltd. The two men believed there was an unmet need in asthma, and in Jiangsu’s drug, a potential game-changer.

The experimental medication, AIO-001, is similar to Amgen and AstraZeneca’s new product Tezspire: Both work by inhibiting the thymic stromal lymphopoietin, or TSLP, which is over-expressed by people with asthma and causes airway inflammation. (Another startup, Upstream Bio, announced Tuesday that its subcutaneous TSLP inhibitor is also showing promise in a Phase 1 trial.)

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In